Urapidil permeates the intact blood-brain barrier.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 7519201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the plasma and cerebrospinal fluid (CSF) levels of urapidil after i.v. administration and the effect on CSF serotonin and 5-hydroxyindoleacetic acid (5-HIAA) concentrations. Open, single-dose study. Post-surgery following neurosurgical removal of the hypophysis (n = 5) or aneurysm clipping (n = 1). 6 patients, aged 32-71 years, with intact blood-brain barrier (BBB); 1 patient was studied twice. Single dose of 25 mg urapidil i.v. as prophylaxis of BP increase during extubation or as treatment of hypertensive episodes. Urapidil, serotonin and 5-HIAA were measured by HPLC in CSF during 8 h after urapidil administration. Urapidil was detected in CSF as soon as 5 min after injection in 3 patients. The concentration ratio of plasma/CSF after the distribution phase was about 5:1. No significant effect on serotonin and 5-HIAA in CSF was seen. After administration of a therapeutic dose, urapidil permeates the BBB and may interact with central 5-HT1A-receptors.
Medical subject headings
- Adrenergic alpha-Antagonists
- Antihypertensive Agents
- Blood-Brain Barrier
- Piperazines